Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: A case report

Medical Oncology

Volumn 30, Issue 2, 2013, Pages

  Iams, Wade ^a   Beckermann, Kathyrn Eby ^a   Neff, Anne T ^a   Mayer, Ingrid A ^a   Abramson, Vandana Gupta ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Carboplatin; Docetaxel; Thrombotic microangiopathy; Trastuzumab

Indexed keywords

CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PREDNISONE; PROGESTERONE RECEPTOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TAXOID;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; DYSPNEA; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; HOSPITAL DISCHARGE; HUMAN; JAUNDICE; LYMPH NODE DISSECTION; MASTECTOMY; MULTIPLE CYCLE TREATMENT; PLASMAPHERESIS; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; URINALYSIS; ADJUVANT CHEMOTHERAPY; BIOSYNTHESIS; BLOOD; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; MIDDLE AGED;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; TAXOIDS; THROMBOTIC MICROANGIOPATHIES;

EID: 84875690063     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0568-x     Document Type: Article

References (14)

1. Pisoni R, Ruggenenti P, Remuzzi G. Drug-induced thrombotic microangiopathy; incidence, prevention, and management. Drug Saf. 2001;24(7):491-501.
2. Symmers W. Thrombotic microangiopathic haemolytic anaemia (thrombotic microangiopathy). Br Med J. 1952;2:897-903.
3. Siau K, Varughese M. Thrombotic microangiopathy following docetaxel and trastuzumab chemotherapy: a case report. Med Oncol. 2010;27:1057-9.
4. Murgo AJ. Cancer- and chemotherapy-associated thrombotic microangiopathy. In: Kaplan BS, Trompeter RS, Moake JL, editors. Hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura, (kidney disease S v. 10), vol. 22. New York: Marcel Dekker Ltd; 1992. p. 271-95.
5. Rahdi M, Carpenter SL. Thrombotic microangiopathies. ISRN Hematol. 2012.
6. Moake JL. Thrombotic microangiopathies. NEJM. 2002;347(8):589-600.
7. Lechner K, Obermeier HL. Cancer-related microangiopathic hemolytic anemia. Medicine. 2012;91:195-205.
8. Walker RW, Rosenblum MK, Kempin SJ, Christian MC. Carboplatin-associated thrombotic microangiopathic hemolytic anemia. Cancer. 1989;64(5):1017-20.
9. Fisher DC, Sherrill GB, Hussein A, Rubin P, Vredenburgh JJ, Elkordy M, Ross M, Petros W, Peters WP. Thrombotic microangiopathy as a complication of high-dose chemotherapy for breast cancer. Bone Marrow Transpl. 1996;18(1):193-8.
10. Dlott JS, Danielson CFM, Blue-Hnidy DE, McCarthy LJ. Drug induced thrombotic thrombocytopenic purpura/haemolytic uremic syndrome: a concise review. Ther Apher Dial. 2004;8(2):102-11.
11. Fields SM, Lindley CM. Thrombotic microangiopathy associated with chemotherapy: case report and review of the literature. DICP. 1989;23(7-8):582-8.
12. Cantrell JE Jr, Phillips TM, Schein PS. Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy. J Clin Oncol. 1985;3(5):723-34.
13. Snyder HW Jr, Mittelman A, Oral A, Messerschmidt GL, et al. Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma. Cancer. 1993;71(5):1882-92.
14. Onitilo AA, Engel JM, Clouse LH, Gerndt KM. Successful treatment of mitomycin-induced thrombotic thrombocytopenic purpura with rituximab. Vasc Interv Radiol. 2009;20(2):275-6.